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Glycogen synthase kinase-3 controls IL-10 expression
in CD4+ effector T-cell subsets through epigenetic
modification of the IL-10 promoter
Elaine V. Hill1, T. H. Sky Ng1, Bronwen R. Burton1, Charly M. Oakley1,
Karim Malik2 and David C. Wraith1
1 School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
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The serine/threonine kinase glycogen synthase kinase-3 (GSK3) plays an important role
in balancing pro- and anti-inflammatory cytokines. We have examined the role of GSK3
in production of IL-10 by subsets of CD4+ T helper cells. Treatment of naive murine CD4+
T cells with GSK3 inhibitors did not affect their production of IL-10. However, treatment
of Th1 and Th2 cells with GSK3 inhibitors dramatically increased production of IL-10.
GSK3 inhibition also led to upregulation of IL-10 among Th1, Th2, and Th17 subsets
isolated from human blood. The encephalitogenic potential of GSK3 inhibitor treated
murine Th1 cells was significantly reduced in adoptive transfer experiments by an IL-10-
dependent mechanism. Analysis of the murine IL-10 promoter in response to inhibition
of GSK3 in Th1 cells showed modification to a transcriptionally active state indicated
by changes in histone H3 acetylation and methylation. Additionally, GSK3 inhibition
increased expression of the transcription factors c-Maf, Nfil3, and GATA3, correlating
with the increase in IL-10. These findings are important in the context of autoimmune
disease since they show that it is possible to reprogram disease-causing cells through
GSK3 inhibition.
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Introduction
IL-10 is essential for protection from immunopathology, allergy,
and autoimmunity and is expressed by a wide variety of innate
and adaptive immune cells [1, 2]. IL-10 production by Th1 cells is
important for their self-regulation, to limit the immune response
and prevent tissue damage in both infection and autoimmune dis-
ease [3–5]. In the Tg4 TCR-transgenic mouse model, repeated
administration of the Ac1-9 peptide of myelin basic protein (MBP)
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leads to induction of Th1 cells secreting IL-10 that protect mice
from experimental autoimmune encephalomyelitis (EAE) [6].
IL-10 secreted by these cells acts on dendritic cells (DCs) and
renders them less effective at priming CD4+ T cells and sup-
presses their differentiation into Th1 cells, thus creating a negative
feedback loop to prevent excessive Th1 inflammation [6]. Th17
cells can also express IL-10, which is enhanced in the absence of
IL-23 [7]. Th2 cells provide a protective response during para-
site infection but are also involved in allergic responses through
the enhancement of IgE induction. IL-10 secretion by Th2 cells is
important in restraining Th2 responses in murine allergy [8] and
Th2-derived IL-10 can act on DCs to prevent further differentiation
of Th2 cells [9].
C© 2015 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
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The serine/threonine kinase glycogen synthase kinase-3
(GSK3) has been shown to have an important role in regulat-
ing IL-10 expression [10, 11]. Inhibitors of GSK3 have been
shown to reduce inflammation in experimental colitis, arthritis,
and peritonitis [12, 13]; they also led to downregulation of pro-
inflammatory cytokines and upregulation of IL-10 in a model of
endotoxin shock [14]. GSK3 inhibition in human memory CD4+
T cells, but not naive cells, was found to increase IL-10 production
and IL-10-dependent suppressive activity [15].
Lithium is an inhibitor of GSK3 that has been used to treat
bipolar disorder in humans for over 50 years [16]. A study treating
C57BL/6 mice with dietary lithium suppressed EAE both prior to
and after disease induction [17]. Furthermore, the generation of
Th1 cells was reduced by GSK3 inhibition, due to impaired STAT1
activation [18], while inhibition of GSK3 in CD4+ T cells led to a
block in IL-6 production and STAT3 activation, thereby preventing
Th17 polarization [19].
In this study, we investigated whether GSK3 inhibition affects
IL-10 production in different subsets of mouse and human CD4+
T cells. While inhibition of GSK3 did not affect IL-10 production
in naive cells, treatment of Th1, Th2, or Th17 cells led to an
increase in IL-10. Epigenetic changes at the IL-10 locus and IL-10-
promoting transcription factors were induced by GSK3 inhibition
of Th1 and Th2 cells leading to the generation of a nonpathogenic
T-cell phenotype. We conclude that GSK3 controls the balance of
pro- and anti-inflammatory cytokines in activated CD4+ T cells and
that inhibition of GSK3 may have therapeutic utility in conversion
of pathogenic CD4+ effector T cells into IL-10-secreting CD4+
T cells.
Results
GSK3 inhibition leads to increased IL-10 production by
Th1, Th2, and Th17 cells
Naive CD4+ T cells were purified from spleens of Tg4 mice that
express TCR specific for the peptide Ac1-9 of MBP and cultured
with Ag-presenting cells (APCs) and peptide. These cells did not
show any change in IL-10 production when cultured in the pres-
ence of GSK3 inhibitors although there was a decrease in the per-
centage of IFN-γ+ cells (Fig. 1A). We used three ATP-competitive
inhibitors, CHIR99021, SB216763, and SB627772, with differing
chemical structures and specificity profiles [20, 21] in order to
minimize off-target effects. To assess the effect of GSK3 inhibitors
on effector T-cell subsets, Tg4 CD4+ T cells were polarized to a Th1
phenotype and then stimulated with APCs in the presence of GSK3
inhibitors. There was an increase in the percentage of cells produc-
ing IL-10 in cultures treated with GSK3 inhibitors (Fig. 1B). There
was a significant increase in the population of IL-10+/IFN-γ+
cells (Fig. 1C). Similar results were observed with the peptide
substrate competitive GSK3 inhibitor L803mts that has previously
been shown not to inhibit other protein kinases [22, 23] (Sup-
porting Information Fig. 1). Unlike the naive cells, there was no
overall decrease in IFN-γ+ cells observed by intracellular cytokine
staining of Th1 cells, however, there was a decrease in the amount
of IFN-γ secreted by Th1 cells in an APC-independent system (Sup-
porting Information Fig. 2); therefore, GSK3 inhibition is able to
reduce IFN-γ expression in both naive and Th1 cells. There was
an increase in polarized Th2 cells producing IL-10 in response
to GSK3 inhibition (Fig. 1D) and there was a particularly large
increase in cells expressing both IL-10 and IL-4 (Fig. 1E). Culture
of polarized Th17 cells with CHIR99021 also led to a small but
significant increase in the percentage of IL-10-expressing cells in
cultures where IL-23 was included during polarization (Fig. 1F
and G).
GSK3 activity in Th1 and Th2 cells cultured with GSK3
inhibitors was assessed by Western blotting of P-CRMP2 (T514),
a GSK3 substrate [24], and this confirmed that GSK3 is inhib-
ited throughout the culture (7 days) with the GSK3 inhibitors
(Supporting Information Fig. 3). The effect of GSK3 inhibitors
on IL-10 production during polarization of Th1, Th2, and Th17
cells was also studied (Supporting Information Fig. 4). There
was a small increase in IL-10 production in Th1 and Th17
polarizing cells and a larger increase in IL-10 in Th2 polariz-
ing cells; interestingly this was mainly from non-IL-4-expressing
cells, unlike established polarized Th2 cells where the increase
was predominantly in IL-4+IL-10+ cells (Fig. 1D). We also inves-
tigated the effect of GSK3 inhibition on the restimulation of
cells cultured with peptide but no polarizing cytokines. These
cells are mainly of a Th1 nature at day 7 and upon res-
timulation with GSK3 inhibitors increase production of IL-10
(Supporting Information Fig. 5).
IL-10 has previously been shown to promote anergy and the dif-
ferentiation of IL-10-secreting Th1 cells [25, 26]. However, during
the induction of IL-10 Tregs in vivo by repeated doses of peptide
in the Tg4 mouse, exogenous IL-10 from sources such as APCs is
not required [6]. To ascertain whether the same is true in the con-
version of Th1 cells to IL-10-producing cells by GSK3 inhibitors,
Th1 cells were cultured with APCs from IL-10−/− mice in the pres-
ence of GSK3 inhibitors. APC-derived IL-10 was not necessary
for the increased production of IL-10 from CD4+ T cells follow-
ing GSK3 inhibition; in fact, exogenous IL-10 partially suppressed
IL-10 secretion (Supporting Information Fig. 6A and B). In similar
experiments carried out in Th2 cells, exogenous IL-10 from APCs
was also redundant for GSK3 inhibition mediated IL-10 induction
(Supporting Information Fig. 6C and D).
In order to assess the requirement for TCR signaling in the
upregulation of IL-10, Th1 and Th2 cells were restimulated with
irradiated APCs in the absence of peptide (Supporting Informa-
tion Fig. 7A and B). These cells did not increase their produc-
tion of IL-10, showing the dependence on TCR signaling for this
upregulation. We also assessed the requirement for the major
Th1 and Th2 cytokines, IFN-γ, and IL-4 and IL-10 signaling by
the addition of blocking antibodies to cultures of Th1 and Th2
cells with GSK3 inhibitor (Supporting Information Fig. 7C and
D). Blocking of these cytokines did not affect the upregulation of
IL-10.
C© 2015 The Authors. European Journal of Immunology published by
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Figure 1. GSK3 inhibitors induce IL-10 production in Th1, Th2, and Th17 cells. (A) Naive CD4+ T cells were isolated from Tg4 splenocytes and
cultured with APCs in the presence of MBP Ac1-9 and GSK3 inhibitors or vehicle control. Intracellular cytokine staining for IFN-γ and IL-10 was
carried out on day 7 of stimulation. Data are plots gated on live CD4+ cells and are representative of three independent experiments. (B) Th1
polarized Tg4 cells were restimulated with APCs in the presence of GSK3 inhibitors or vehicle control and MBP Ac1-9. IL-2 was added on day
3 of culture and intracellular cytokine staining for IFN-γ and IL-10 was carried out on day 7. Data are plots gated on live CD4+ cells and are
representative of five independent experiments. (C) Pooled quantitation of IL-10+/ IFN-γ+ cells from five independent experiments as shown in (B).
Data are mean + SEM. *p < 0.05 (ANOVA, Dunnett’s multiple-comparison posttest). (D) Th2 polarized Tg4 cells were restimulated with APCs in the
presence of GSK3 inhibitors or vehicle control and MBP Ac1-9. IL-2 was added on day 3 of culture and intracellular cytokine staining for IL-4 and
IL-10 carried out on day 7. Data are plots gated on live CD4+ cells and are representative of four independent experiments. (E) Pooled quantitation
of IL-10+/ IL-4+ cells from four independent experiments as shown in (D). Data are mean + SEM. *p < 0.05 (ANOVA; Dunnett’s multiple-comparison
posttest). (F) Tg4 splenocytes were cultured under Th17 polarizing conditions with/without IL-23 added on day 3 of culture. On day 7 of culture,
Th17 cells were restimulated with APCs in the presence of CHIR99021 or vehicle control and MBP Ac1-9. Intracellular cytokine staining for IL-17
and IL-10 was carried out on day 7 of stimulation. Data are plots gated on live CD4+ cells and are representative of six independent experiments.
(G) Pooled quantitation of IL-10+ cells from six independent experiments as shown in (F). Data are mean + SEM. NS, not significant; *p < 0.05
(Student’s t-test).
C© 2015 The Authors. European Journal of Immunology published by
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Figure 2. GSK3 inhibitors act directly on CD4+ T cells to induce IL-10
production in Th1, Th2, and Th17 cells. (A) Naive CD4+ T cells were
isolated from Tg4 splenocytes and cultured with anti-CD3 and anti-
CD28 in the presence of IL-2 and GSK3 inhibitors or vehicle control.
Tissue culture supernatants were taken on day 7 of stimulation and
analyzed for IL-10 by fluorescent bead immunoassay. Data are mean +
SEM pooled from three independent experiments with triplicate wells.
NS, not significant (ANOVA). (B) Th1 polarized Tg4 cells were restim-
ulated with anti-CD3 and anti-CD28 in the presence of IL-2 and GSK3
inhibitors or vehicle control. Tissue culture supernatants were taken
GSK3 inhibitors act directly on CD4+ T cells to induce
IL-10 production in Th1, Th2, and Th17 cells
To investigate the requirement for APCs during GSK3 inhibition
mediated induction of IL-10 in CD4+ T cells, naive or polarized
Tg4 CD4+ T cells were cultured with anti-CD3/ anti-CD28 stim-
ulation in the presence of GSK3 inhibitors and IL-10 secretion
was assessed. Naive CD4+ T cells did not show any increase
in IL-10 secretion (Fig. 2A); however, both Th1 and Th2 cul-
tures showed a substantial increase in IL-10 production (Fig. 2B
and C), proving that GSK3 inhibitors act directly on the polar-
ized CD4+ Th1 and Th2 cells. Polarized Th17 cells, cultured with
GSK3 inhibitors, also upregulated IL-10 secretion (Fig. 2D) both
with and without IL-23 during Th17 differentiation although the
total IL-10 secreted was much lower than in murine Th1 or Th2
cells.
GSK3 inhibition causes IL-10 upregulation in human
Th1, Th2, and Th17 cells
We extended our studies to human CD4+ T cells and found
that although naive cells showed a small, nonsignificant trend
toward increased IL-10, memory cells responded with a signifi-
cant increase in the percentage of cells expressing IL-10 (Fig. 3A).
Cell sorting based on chemokine receptor expression, as described
previously [22, 23], enriched populations of IFN-γ-producing Th1
cells, IL-4-secreting Th2 cells, and IL-17A-expressing Th17 cells
from human blood (Supporting Information Fig. 8). These purified
subsets were cultured with polyclonal stimulation in the presence
of CHIR99021, the most specific commercially available GSK3
inhibitor [20]. Similar to our findings in the mouse, IL-10 was
upregulated in each of the human subsets examined (Fig. 3B
and C).
GSK3 inhibition reduces the pathogenicity of Th1 cells
IL-10 has previously been shown to mediate protection from EAE
when tolerance was induced in mice by repeated intranasal doses

on day 7 of stimulation and analyzed for IL-10 by ELISA. Data are mean
+ SEM pooled from five independent experiments with triplicate wells.
*p < 0.05, **p < 0.01 (ANOVA, Dunnett’s multiple-comparison posttest).
(C) Th2 polarized Tg4 cells were restimulated with anti-CD3 and anti-
CD28 in the presence of IL-2 and GSK3 inhibitors or vehicle control.
Tissue culture supernatants were taken on day 7 of stimulation and
analyzed for IL-10 by ELISA. Data are mean + SEM pooled from five
independent experiments with triplicate wells. **p< 0.01 (ANOVA, Dun-
nett’smultiple-comparison posttest). (D) Tg4 splenocyteswere cultured
under Th17 polarizing conditions with/without addition of IL-23 on day
3. On day 7 of culture, Th17 CD4+ cells were isolated and restimulated
with anti-CD3 and anti-CD28 in the presence of CHIR99021 or vehicle
control. Tissue culture supernatants were taken on day 7 of stimulation
and IL-10 was quantified by ELISA. Data are mean + SEM pooled from
five independent experiments with triplicate wells. **p < 0.01 (ANOVA,
Dunnett’s multiple-comparison posttest).
C© 2015 The Authors. European Journal of Immunology published by
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Figure 3. GSK3 inhibitors induce IL-10 production in human Th1,
Th2, and Th17 cells. (A) Naive or memory CD4+ T cells were iso-
lated from PBMCs by magnetic selection and stimulated with anti-
CD3 and anti-CD28 in the presence of IL-2 and CHIR99021, SB216763,
SB627772, or vehicle control. Intracellular cytokine staining was carried
out on day 10. Graphs show the percentage (mean + SEM) of viable
CD4+ T cells that are IL-10+ in each condition (naive n = 4, mem-
ory n = 10 donors). NS, not significant; *p < 0.05, **p < 0.01 (ANOVA,
Dunnett’s multiple-comparison posttest). (B) Human effector CD4+ T-
cell subsets were isolated from PBMCs by flow cytometric sorting. Th1
cells (CD4+CXCR3+), Th2 cells (CD4+CXCR3−CCR4+CCR6−), or Th17 cells
(CD4+CXCR3−CCR4+CCR6+) were cultured with autologous APCs, anti-
CD3, IL-2, andCHIR99021 or vehicle control. Intracellular cytokine stain-
ing was carried out on day 7. Dot plots show cytokine production by live
CD4+ cells. Data are representative of three independent experiments.
(C) Tissue culture supernatants were taken on day 2 of culture and ana-
lyzed for IL-10 by fluorescent bead immunoassay. Data show mean +
SEM of three pooled independent experiments. **p < 0.01, ***p < 0.001
(t-test).
of peptide [27]. We, therefore, tested whether the increased secre-
tion of IL-10 from GSK3 inhibitor treated Th1 cells would have a
protective role in EAE. Th1 cells were cultured +/- GSK3 inhibitor
and adoptively transferred to Tg4 mice to induce EAE. Culture of
Th1 cells with GSK3 inhibitor resulted in a decrease in EAE sever-
ity, which was sustained for the entire disease course (Fig. 4A).
Mice receiving a control isotype Ab showed a significant decrease
in disease burden compared with mice receiving control Th1 cells
(Fig. 4B); however, mice receiving GSK3 inhibitor treated cells and
anti-IL-10R Ab displayed an increase in disease burden compared
with controls (Fig. 4B).
GSK3 inhibition causes epigenetic changes in the
IL-10 promoter in murine and human CD4+ T cells
IL-10-mediated suppression of EAE in mice receiving GSK3
inhibitor treated Th1 cells by adoptive transfer was sustained
throughout the 20-day course of the experiment, suggesting that
the cellular changes effected by the inhibitor were long lasting.
Indeed, Th1 cells cultured with inhibitor expressed higher levels
of IL-10 than controls for several rounds of restimulation after
inhibitor removal (Fig. 5A–C). This led us to investigate the epige-
netic status of the IL-10 promoter since epigenetic changes are able
to influence prolonged changes in gene expression. ChIP analysis
of the murine IL-10 promoter, using four primer sets spanning the
promoter (Fig. 5D), revealed a significant GSK3 inhibitor induced
increase in histone H3 acetylation, a marker for active gene tran-
scription (Fig. 5E). There was also a modest increase in histone
H3 trimethylation (H3K4me3, Fig. 5F). Strikingly, however, there
were dramatic decreases in two repressive histone marks, histone
H3 lysine 9 dimethylation (H3K9me2) and histone H3 lysine 27
trimethylation (H3K27me3) following GSK3 inhibitor treatment
of Th1 cells (Fig. 5G and H).
We also investigated whether similar epigenetic modifications
occurred in human CD4+ effector T cells. Memory CD4+ T cells
were analyzed for the presence of H3K4me3 and H3K27me3, in
the IL-10 promoter after culture with GSK3 inhibitor (Fig. 6A–
C). Changes in these chromatin modifications were remarkably
similar to those observed in murine Th1 cells with a significant
upregulation of H3K4me3 at the regions covered by primer sets
S2 and S4 (Fig. 6B) and a decrease in H3K27me3 across the IL-10
promoter (Fig. 6C).
GSK3 inhibitor treatment of Th1 cells causes the
upregulation of Nfil3, c-Maf, and GATA3
GSK3 is known to influence several transcription factors (reviewed
in [10, 11]). We, therefore, examined the expression of three
transcription factors, Nfil3, c-Maf, and GATA3, previously shown
to affect IL-10 production in CD4+ T cells. Analysis by mRNA
quantitation and protein expression in murine cells showed an
increase in each of these transcription factors in Th1 cells upon
GSK3 inhibition (Fig. 7A, C, and E). Levels of all three transcrip-
tion factors were found to be higher in Th2 cells than in Th1
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
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Figure 4. GSK3 inhibition abrogates the ability of Th1 cells to induce
EAE in an IL-10-dependent manner. Th1 polarized Tg4 cells were res-
timulated with APCs and MBP Ac1-9 in the presence of CHIR99021 or
vehicle control. IL-2 was added on day 3 of restimulation and on day
4, 107 Th1 cells were adoptively transferred to Tg4 mice by i.p. injec-
tion. Recipient mice were also injected with anti-IL-10R Ab or isotype
control (500 μg) on the day of transfer (day 0) and on day 7. EAE was
scored daily. Three similar experiments were performed. Each group
contained five to six mice. (A) Time course of disease progression. Data
show the mean EAE score and SEM from each day. (B) Disease burden
in EAE days was calculated for each mouse (median; error bars show
minimum and maximum disease burden in each group; box extends
from the 25th to 75th percentiles). Themedian score for the control iso-
type IgG group was significantly different from that of the CHIR99021
isotype IgG group and the CHIR99021 isotype IgG group was signifi-
cantly different from that of the CHIR99021 anti-IL-10R group. *p < 0.05
(Mann–Whitney U test).
cells. GATA3 and Nfil3 expression was further increased in Th2
cells upon GSK3 inhibition, however, no change was observed in
c-Maf in Th2 cells (Fig. 7B, D, and F). Both GATA3 and c-Maf
are known to be important transcription factors in Th2 cells
[28, 29], however, no upregulation of IL-4 upon GSK3 inhibition
was observed in either Th1 or Th17 cells (Supporting Information
Fig. 9) and, additionally, no difference in phospho-STAT6 lev-
els in Th1 or Th2 cells cultured with GSK3 inhibitor (Supporting
Information Fig. 10)
Discussion
We have extended previous studies by analyzing the effect of GSK3
inhibition on CD4+ effector T-cell subsets; Th1, Th2, and Th17 lin-
eages all responded to GSK3 inhibitors with an increase in secreted
IL-10 protein. Adoptive transfer of GSK3 inhibitor treated Th1 cells
demonstrated the protective effect of IL-10 secreted by these cells.
Lithium treatment was previously shown to decrease severity of
EAE whether treatment was administered prior to or after disease
onset [17]. Lithium was found to decrease peptide-induced IL-6,
IL-17, and IFN-γ from T cells; the authors suggested the effect on
EAE could be due to a reduction in Th17 cells. A subsequent study
showed that GSK3 inhibition blocked the differentiation of Th17
cells [19]. In a further model of Th1-induced EAE, lithium was
shown to induce IL-27 in the CNS of mice [30] with a trend toward
increased IL-10. We have shown that GSK3 inhibition is able to
directly induce IL-10 production in CD4+ T cells without con-
comitant production of IL-27 by APCs (data not shown); however,
it is possible that IL-27 production may contribute to IL-10 pro-
duction in vivo. Another study found that GSK3 inhibition led to
reduced differentiation of Th1 cells and decreased severity of Th1-
mediated EAE [18]. If GSK3 inhibitors were administered after the
onset of disease then amelioration of symptoms was also observed
[18]. In our study, Th1 cells were used to induce disease and the
protective effect of GSK3 inhibition was principally through the
induction of IL-10 secretion. Therefore, GSK3 inhibitors may be
therapeutic in either Th1- or Th17-driven conditions since GSK3
inhibition also ameliorates Th17-related pathology through IL-10-
independent mechanisms.
Th2 differentiated cells upregulated IL-10 upon GSK3 inhibitor
treatment and this may be important in the context of allergen-
specific immunotherapy. Ag-specific immunotherapy in allergy
to house dust mite, birch pollen, bee venom, and grass pollen
[31–33] is characterized by an increase in IL-10-producing
T cells. IL-10 may have an important role in regulating the balance
between IgE and IgG4 antibodies with associated counterinflam-
matory consequences [34]. In the presence of IL-4, an increase in
IL-10 leads to a preferential class switch in favor of IgG4 and both
total and allergen-specific IgE responses are suppressed [35, 36].
This beneficial effect of a rise in IL-10 in the presence of IL-4, as
seen in this study, suggests that GSK3 inhibition may be a useful
tool in allergen-specific immunotherapy.
There are several levels of control of differentiation of CD4+
T cells. Transcription factors such as T-bet for Th1 cells and FoxP3
for Treg cells are crucial for the regulation of lineage-specific
gene expression. However, epigenetic mechanisms also emerge
as critical regulators of differentiation (reviewed in [37–39]).
PTMs of histones affect gene expression by altering DNA accessi-
bility. Epigenetic changes may influence both differentiation and
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
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Figure 5. Stability of IL-10 expres-
sion and epigenetic analysis of the
IL-10 promoter. (A) Schematic dia-
gram showing experimental time-
course. Th1 polarized Tg4 cells were
restimulated with APCs in the pres-
ence of GSK3 inhibitors or vehicle
control and MBP Ac1-9. IL-2 was
added on day 3 of culture. On day 7
of restimulation, CD4+ T cells were
restimulated with APCs in the pres-
ence of MBP Ac1-9 only (with no
inhibitors). On day 7 CD4+ T cells
were restimulated again with APCs
only in the presence of MBP Ac1-
9. (B) Intracellular cytokine staining
for IFN-γ and IL-10 was carried out
on day 7 of the final round of res-
timulation. Data are plots gated on
live CD4+ cells and are represen-
tative of three independent exper-
iments. (C) Tissue culture super-
natants were taken on day 3 of
the final round of stimulation and
analyzed for IL-10 by ELISA. Data
are mean + SEM of triplicate wells
and are representative of two inde-
pendent experiments. (D) Schematic
diagram showing the positions of
primer sets used in murine ChIP
experiments. Four sets of primers
spanning the IL-10 promoter (S1–
S4) were used together with non-
promoter control primers (C2). Con-
sensus transcription factor binding
sites are shown. (E–H) Tg4 spleno-
cytes were cultured in the presence
of MBP Ac1-9 under Th1 polarizing
conditions. On day 7 of culture, Th1
cells were restimulated with APCs in
the presence of CHIR99021 or vehi-
cle control as well as MBP Ac1-9 for
further 7 days. IL-2 was added on
day 3 of culture. Live CD4+ T cells
were selected and ChIP analysis car-
ried out using antibodies against
acetyl histone H3 (E), H3K4me3 (F),
H3K9me2 (G), and H3K27me3 (H).
Graphs show the mean amount of
immunoprecipitated DNA compared
to the total amount of DNA, ± SEM,
for three independent experiments.
NS, not significant; *p < 0.05,
**p < 0.01, ***p < 0.001 (t-test).
maintenance of cellular phenotype as the changes in chromatin
structure are maintained in cells and inherited by their descen-
dants [40]. Several groups have previously found a correlation
between epigenetic modifications and gene expression in CD4+
T cells [41–45].
Histone H3 acetylation and Lys-4 trimethylation (H3K4me3)
permit greater accessibility of DNA to transcription fac-
tors, whereas Lys-27 trimethylation (H3K27me3) or Lys-9
dimethylation (H3K9me2) are associated with gene repression.
While these methylation events on H3 have clear contrasting
effects on gene expression, it is believed that genes marked with
both H3K4me3 and H3K27me3 remain in a “poised” state ready
for later activation [46]. Although CD4+ T cells have been thought
to be distinct lineages defined by the transcription factors they
express and the cytokines they produce, there is in fact con-
siderable plasticity in CD4+ T-cell fate [47]; indeed, there are
several possible combinations of activating and repressive mod-
ifications [48]. This flexibility may allow the capacity for more
adaptive responses in a changing environment or immunological
challenge.
Here we have studied changes in H3 modification at the IL-10
promoter in response to inhibition of GSK3. In murine Th1 cells,
GSK3 inhibition effects a change in the chromatin modifications
associated with the IL-10 promoter from the repressive H3K9me2
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
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Figure 6. Epigenetic analysis of the IL-10 promoter in human memory T cells. (A) Schematic diagram showing the positions of primer sets used
in human ChIP experiments. Four sets of primers spanning the IL-10 promoter (S1-S4) were used together with nonpromoter control primers (C2).
Consensus transcription factor binding sites are shown. Memory CD4+ T cells were isolated from PBMC bymagnetic selection and stimulated with
anti-CD3 and anti-CD28 in the presence of IL-2 and CHIR99021 and vehicle control for 7 days. Live CD4+ T cells were selected and ChIP analysis
carried out using antibodies against H3K4me3 (B) and H3K27me3 (C). Graphs show the mean amount of immunoprecipitated DNA compared to
the total amount of DNA, ± SEM, for four independent experiments. NS, not significant; *p < 0.05, **p < 0.01, ***p < 0.001 (t-test).
and H3K27me3 to the activating H3Ac and H3K4me3 and
these changes may allow the chronic maintenance of the IL-10-
expressing phenotype. In human memory CD4+ T cells, we also
observed an increase in H3K4me3 and a decrease in H3K27me3
at the IL-10 promoter upon GSK3 inhibition, strengthening our
suggestion that GSK3 inhibition may be a means of upregulating
IL-10 production in autoimmune or allergic disease.
Epigenetic changes in gene expression can be facilitated by
environmental agents and so may be particularly important in the
development of autoimmune disease, which is thought to occur
in genetically susceptible individuals exposed to an environmen-
tal trigger [49–51]. Therefore, the changes in cytokine produc-
tion in CD4+ T cells elicited by GSK3 inhibition may also sug-
gest a mechanism whereby dysregulation of GSK3 may render an
individual susceptible to autoimmune disease; in fact, a particu-
lar allelic variant of GSK3β is a susceptibility factor for multiple
sclerosis [52].
Epigenetic changes involve the physical remodeling of chro-
matin structure that in turn regulates accessibility to transcrip-
tion factors. GSK3 is known to influence the activity of many
transcription factors and regulate transcription of cytokines in
several other systems studied [10, 53]. Nfil3 is known to influ-
ence IL-10 expression in both Th1 and Th2 cells [54–56]. c-Maf is
essential for IL-10 expression in macrophages [57] and its expres-
sion correlates with IL-10 expression in CD4+ T cells [58–60].
GATA3 induces the differentiation of Th2 cells and inhibits that of
Th1 cells [28, 61]. Our observations show that Nfil3 and GATA3
are upregulated upon GSK3 inhibition in Th1 and Th2 cells and
c-Maf is significantly upregulated in Th1 cells only. c-Maf is highly
expressed in Th2 cells and so it is possible that further upregula-
tion is not possible or that the c-Maf locus in Th2 cells is modified
in a manner that precludes further upregulation by GSK3 inhibi-
tion. Interestingly, GATA3 has also been shown to induce changes
in the chromatin structure at the IL-10 locus in the absence and
presence of IL-4 [62] and Nfil3 has also been reported to influence
histone modifications [63]. Therefore, the increase in GATA3 and
Nfil3 expression upon GSK3 inhibition could be contributing to
the changes in histone modifications observed in this study. These
findings elucidate a novel regulation of these transcription fac-
tors by GSK3 and their upregulation correlating with the increase
in IL-10. We conclude that GSK3 inhibition leads to a stable
upregulation of IL-10 in Th1 and Th2 cells, which may be ben-
eficial in the development of new therapies for autoimmune and
allergic diseases.
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Figure 7. Transcription factor expression changes induced by GSK3 inhibition. Tg4 splenocytes were cultured in the presence of peptideMBP Ac1-9
(10 μg/mL) under Th1 or Th2 polarizing conditions. On day 7 of culture, Th1 and Th2 cells were restimulatedwith APCs in the presence of CHIR99021
or vehicle control as well as peptide MBP Ac1-9 (10 μg/mL) for further 7 days. IL-2 was added on day 3 of culture. (A and B) mRNA was purified from
live CD4+ T cells for RT-PCR analysis. Graphs showmRNA expression relative to the housekeeping gene hypoxanthine phosphoribosyltransferase
1 (HPRT1) for five pooled experiments. NS, not significant; ***p< 0.001 (t-test). (C–F) Cells were stimulated with PMA and ionomycin and intracellular
transcription factor staining was carried out. Results were gated on live CD4+ cells and the geometric mean florescence of transcription factor
staining was calculated using FlowJo software. Graphs show mean ± SEM. A paired two-tail t-test analysis was carried out on pooled data from
five independent experiments. NS, not significant; *p < 0.05.
Materials and methods
Experimental mice were maintained under specific pathogen-free
conditions. B10.PL (H2u) mice were obtained from The Jackson
Laboratory. The Tg4 TCR transgenic mouse expressing Vβ8.2 TCR
specific for MBP Ac1-9 and the B10.PL IL-10−/− mouse have
been described previously [6]. All experiments were approved
by the UK Home Office and performed according to animal wel-
fare codes directed by the University of Bristol ethical review
committee.
Murine cell separation
Purified CD4+ T cells were isolated by magnetic separation using
the CD4+ T cell Isolation kit II (Miltenyi Biotec) or the EasySep
Mouse Naive CD4+ T cell Isolation Kit (Stemcell Technologies).
Murine cell culture
Splenocytes were cultured in RPMI medium (Lonza) containing
heat-inactivated FCS (5%, BioSera), HEPES buffer (Lonza),
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β-mercaptoethanol (Gibco), glutamine and penicillin/
streptomycin (both Lonza) as well as 10 μg/mL peptide
Ac1-9 of MBP (AcASQKRPSQR; GL Biochem, Shanghai). For
Th1 polarization rmIL-12 (5 ng/mL; Peprotech) and anti-IL-4
(11B11; 10 μg/mL, BioXCell) were added and for Th2 polar-
ization rmIL-4 (10 ng/mL, Peprotech) and anti-IFN-γ (XMG1.2)
(10 μg/mL, BioXCell) were added. For Th17 polarization rmIL-6
(25 ng/mL, Peprotech), rmIL1β (10ng/mL, Peprotech), rhTGF-β1
(2ng/mL, Peprotech), anti-IFN-γ (XMG1.2, 25 μg/mL), and
anti-IL-4 (11B11, 10 μg/mL) were added. rhIL-2 (R&D Systems)
was added at 20 U/mL on day 3 for both Th1 and Th2 cultures
and rhIL-23 (Peprotech) at 5 ng/mL for Th17 cultures. GSK3
inhibitors were used at the following predetermined optimal
concentrations: CHIR99021 (2 μM, Tocris), SB216763 (5 μM,
Tocris), SB627772 (10 μM, supplied by GlaxoSmithKline (Steve-
nage) or synthesized by Avistron Chemistry Services), L803mts
(100 μM, Tocris). On day 7, live CD4+ T cells were isolated by
Ficoll centrifugation and restimulated with irradiated B10.PL
splenocytes. Alternatively, live CD4+ T cells were isolated by
Ficoll centrifugation and then magnetic separation using the
CD4+ T cell Isolation kit II and restimulated with either anti-CD3
and anti-CD28 coated beads (Dynabeads, Life Technologies)
or on anti-CD3 (1 μg/mL, eBioscience; clone 145-2C11) and
anti-CD28 (2 μg/mL, eBioscience; clone 37.51) coated plates.
Intracellular cytokine and transcription factor staining
Cells were stimulated with medium containing PMA (5ng/mL),
ionomycin (500 ng/mL), and GolgiStop (BD Biosciences) for 3 h
at 37°C. Cells were stained with fixable viability dye ef780 (eBio-
science) and then surface-stained with anti-CD4 Alexa700. Fol-
lowing incubation with IC fixation buffer (eBioscience), cells were
stained intracellularly with anti-IFN-γ PECy7, anti-IL-10 allophy-
cocyanin, anti-IL-17A PE, and/ or anti-IL-4 PE (all eBioscience).
For intracellular transcription factor staining, cells were fixed by
incubation with the FoxP3 Staining Buffer Set (eBioscience). The
antibodies anti-CD4 FITC, anti-Nfil3 PE, and anti-c-Maf ef660 and
their corresponding isotype controls (all eBioscience) were used.
Fluorescence intensity was measured on a BD LSR II flow cytome-
ter and analyzed using FlowJo (Tree Star Inc.) software. FACS
gating strategy is shown in Supporting Information Method 1.
Cytokine protein levels
IL-10 levels in tissue culture supernatant were measured using
a FlowCytomix fluorescent bead immunoassay (eBioscience)
according to manufacturer’s instructions. Fluorescence intensity
was measured on a BD Calibur flow cytometer and analyzed
using FlowCytomix Pro software (eBioscience). IL-10 protein lev-
els were also measured using ELISA with paired antibodies accord-
ing to the manufacturer’s instructions (Peprotech). IFN-γ protein
levels were measured using ELISA with paired antibodies (BD
Biosciences). Optical densities were read at 450/595 nm on a
Spectramax190 microplate reader and analyzed using SoftMax
Pro software (Molecular Devices).
Isolation of human T-cell subsets
CD leukocyte cones from healthy volunteers were obtained
from the National Health Service Blood and Transplant. Ethical
approval was granted by NHS-research ethical committee (NHS-
REC 13/NW/0275). PBMCs were isolated by Ficoll separation.
Magnetic-based techniques were then used to isolate naive, mem-
ory, and CD4+ T cells (Naive CD4+ T cell isolation kit II, Memory
CD4+ T cell isolation kit and CD4+ T cell isolation kit II, respec-
tively, all from Miltenyi Biotec). Naive or memory cell purity was
greater than 95%, based on expression of CD45RA or CD45RO,
respectively. For flow cytometric sorting of effector cell subsets,
pre-enriched CD4+ T cells were stained for CD4, CXCR3, CCR4,
and CCR6, with 7-AAD, and sorted three ways using a BD Influx
cell sorter (BD Biosciences); Th1 cells (viable CD4+CXCR3+), Th2
cells (viable CD4+CXCR3−CCR4+CCR6−), or Th17 cells (viable
CD4+CXCR3−CCR4+CCR6+).
Culture of human T-cell subsets
Naive and memory human CD4+ T cells were cultured on anti-
CD3 (clone OKT3, 10 μg/mL; BioXCell) and anti-CD28 (clone 9.3,
2μg/mL; BioXCell) coated plates with 20 U/mL IL-2 in RPMI 1640
(Lonza), supplemented with 10% heat-inactivated FCS (BioSera),
penicillin/streptomycin and 2 mM L-glutamine (both Lonza),
2-mercapto-ethanol (Gibco), HEPES buffer (Lonza), 100 mM
sodium pyruvate (Gibco), and and 1% nonessential amino acids
(Sigma). Cells were split and media replenished as necessary.
Th1, Th2, and Th17 cells were cultured with autologous
irradiated APCs (CD4− cells) at a 1:5 ratio, with 100 U/mL
IL-2 and 1 μg/mL anti-CD3 (OKT3) in X-VIVO 15 media
(Lonza), supplemented with 5% human AB serum (Sigma),
penicillin/streptomycin, and L-glutamine. GSK-3 inhibitors were
added as above and cells were split as necessary. To determine
cytokine production, on day 7 of T-cell culture, cells were stim-
ulated with PMA (50 ng/mL) and ionomycin (1 μg/mL) for
4 h, in the presence of Golgi Stop. Cells were stained with fixable
viability dye ef780 (eBioscience) and surface-stained with anti-
CD4 Alexa700. Following fixation and permeabilization, intracel-
lular staining for anti-IL-10 ef660, anti-IFNγ PerCPCy5.5, anti-
IL-17A PE, and anti-IL-4 FITC (all eBioscience) was carried
out.
EAE
EAE was induced in Tg4 mice on day 0 by i.p. injection of
107 Th1 cells. Clinical signs of EAE were assessed daily with a
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scoring system as follows: 0, no disease; 1, flaccid tail; 2, impaired
righting reflex and/ or partial hind-leg paralysis; 3, total hindlimb
paralysis; 4, fore- and hindlimb paralysis; 5, moribund or dead.
ChIP analysis
ChIP was carried out using the EZ-Magna ChIP A Chromatin
Immunoprecipitation Kit (Millipore). A total of 20 × 106 CD4+
T cells were fixed in 1% formaldehyde (Fisher Scientific). Glycine
buffer was added to quench any remaining formaldehyde. Cells
were then lysed and sonicated using a Diagenode bath sonicator at
high setting with 30-s pulses over a 5-min period. Immunoprecip-
itation was carried out using the following antibodies: anti-acetyl-
histone H3 (Millipore), ChIPAb+ Trimethyl-Histone H3(Lys4)
(Millipore), ChIPAb+ Trimethyl-Histone H3(Lys27) (Millipore),
anti-Histone H3 (di methyl K9) (Abcam), and rabbit IgG (Milli-
pore). Real-time PCR analysis was carried out using the MJ Opti-
con 2 thermo cycler (MJ Research) and Platinum SYBR Green
qPCR SuperMix-UDG (Invitrogen). Cycling conditions were set up
according to the manufacturer’s instructions; annealing tempera-
ture for all primers was 55°C with 40 cycles of amplification. For
ChIP primers and statistical analysis, see Supporting Information
Method 2.
mRNA analysis
Total mRNA from 3–5× 106 CD4+ T cells after overnight anti-CD3
and anti-CD28 stimulation was isolated using RNAeasy Mini Kit
(Qiagen) and quality and quantity were verified using a Nanodrop
(Thermo scientific). cDNA synthesis was carried out using Super-
Script III First-strand Synthesis SuperMix for qRT-PCR (Invitro-
gen). Real-time PCR was carried out using the MJ Opticon 2
thermo cycler (MJ Research) and Taqman probes (GATA3, NFIL3,
c-Maf, IL-10, HPRT1; Life Technologies). Expression of the target
gene was obtained by using the following equation: target gene
expression = 2(mean HPRT1 ct − mean target gene ct).
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